2023–2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states

• DOI: 10.1016/j.vaccine.2025.127120
• Publication Date: 2025-04-23T21:02:37Z
• Authors: Leah J. McGrath; Farid L. Khan; Santiago M.C. Lopez; Matthew A. Brouil...; Kathleen M. Andersen; Tiange Yu; Benjamin T. Carter; Laura A. Puzniak; John M. McLaughlin
• Keywords: Cumulative incidence

Uptake of COVID-19 vaccines has declined over time, however, little data exist describing uptake among the immunocompromised who remain at high risk severe disease. We evaluated XBB vaccine during 2023-2024 season persons had previously received a in two large, diverse US states. Using from state registries linked to insurance claims, we conducted retrospective cohort study individuals ≥6 months age living California or Louisiana as September 11, 2023 (1) continuous pharmacy and medical enrollment an plan reported by HealthVerity, (2) met Centers for Disease Control Prevention criteria moderately severely (HIV/AIDS primary immunodeficiency, hematologic malignancy prior year, solid organ bone marrow transplant years, use immunosuppressive therapy 210 days), (3) least one dose vaccine. calculated cumulative incidence receipt through March 31, 2024, stratified state, group, specific immunocompromising condition. A total 321,896 (median 55 years; 57 % female) 43,250 45 64 selection Louisiana, respectively. In both states, most common category was (78 85 respectively). Only 21 6 2024. similar across conditions. During respiratory virus season, these 2 states low, with fewer than receiving dose. Enhanced efforts increase this vulnerable population are needed.